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ABSTRACT 
Background: There is uncertainty regarding the optimal timing for initiation of oral 
anticoagulant treatment (OAC) in patients with recent ischaemic stroke and atrial fibrillation 
(AF). We surveyed the current UK practice and assessed clinician’s opinions of when to use 
OAC in recent stroke patients with AF. 
 
Methods: An online survey was sent to stroke physicians within the United Kingdom via their 
national societies.  
 
Results: One hundred and twenty-one clinicians responded to the survey. Ninety-five percent 
of responders agreed there was uncertainty regarding timing of OAC initiation after AF-
related ischaemic stroke. Thirty-six percent of responders followed the ‘1-3-6-12’ European 
Society of Cardiology (ESC) guidelines recommendation. Uncertainty was greater in cases of 
moderate stroke than in cases of TIA, mild or severe stroke. Eighty-eight percent of 
responders would be willing to participate in a clinical trial of early vs. later initiation of OAC 
after stroke. Direct-acting oral anticoagulant (DOAC) were the preferred OAC of choice. 
 
Conclusion: There is a lack of consensus amongst stroke physicians for when to initiate OAC 
to prevent recurrence in stroke patients with AF. There is little uncertainty regarding TIA. A 
clinical trial assessing use of early vs. later initiation of DOAC in patients with recent 
ischaemic stroke and AF would be beneficial.  
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INTRODUCTION 
Atrial fibrillation (AF) is the most common heart rhythm disturbance in the UK1 and confers 
a near 5-fold risk of stroke.2,3,4 The risk of stroke recurrence following AF-related stroke is 
also especially high during the first fourteen days.5,6,7 Oral anticoagulants (OAC) reduce 
recurrence risk by two-thirds.8 Given the high early recurrence risk, use of OAC as early as 
possible seems desirable, but OAC use is associated with increased risk of intracerebral 
haemorrhage (ICH), including symptomatic ICH (sICH) after ischaemic stroke. Balancing 
these possible benefits and risks is challenging. 
 
The European Society of Cardiology (ESC) guidelines recommend that OAC should be 
initiated between one and twelve days in patients with AF and recent acute ischaemic stroke 
depending on the stroke severity.9 This ‘1-3-6-12’ day rule states OAC would be started on 
day 1 following a TIA, day 3 following a mild stroke, day 6 following a moderate stroke and 
on day 12 following severe stroke.10 This pragmatic guidance is based on “expert opinion” 
and such practice evolved during a time where only vitamin K antagonists (VKA) and 
heparins were available. Direct-acting oral anticoagulants (DOACs) are at least as effective 
as VKAs in preventing recurrent stroke in patients with ischaemic stroke and AF. DOACs 
have a rapid onset of action (0.5-4 hours) along with lower rates of ICH.9 It may therefore be 
safer to use these drugs very early after stroke compared to VKA, but exactly when, and in 
whom, the balance of risk and benefit is in favour is unclear. 
 
Whilst there is considerable uncertainty on the optimal latency after acute stroke at which 
OACs should commence, the magnitude of this uncertainty, and the minimum and maximum 
delays that are acceptable to stroke physicians are unclear.  Clarity in this regard would help 
inform the need and design of clinical trials in this area. We conducted a survey aimed to 
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establish specialist opinion and current practice on the timing of OAC initiation in patients 
with recent ischaemic stroke and AF within the United Kingdom. 
 
 
METHODS 
The study was discussed with the West of Scotland Research Ethics Service and formal 
review was not required under the Governance Arrangements for Research Ethics 
Committees. A survey was created online using www.onlinesurveys.ac.uk. An online format 
was used to maximise response return and ease of dissemination. Questions aimed to assess 
what clinicians do in practice, rather than assess knowledge of guidelines. The survey 
consisted of 22 questions (see Online-only Supplemental Data). The first four explored 
demographic data of responders. Further questions explored whether clinicians followed the 
‘1-3-6-12’ day rule, whether they were uncertain regarding when to initiate OAC, and 
whether clinicians would be willing to participate in related clinical trials. Finally, the survey 
included four clinical vignettes of people with TIA and different severities of stroke. In each 
scenario, the patient had AF, no contraindications for anticoagulation, and scenarios were 
consistent regarding age, sex and cardiovascular risk factors (only severity of stroke differed), 
(see Online-only Supplemental Data for the clinical vignettes) Responders were asked to give 
their view on the optimal time to start OAC, and the earliest and latest times they would be 
willing to start OAC in a clinical trial for each scenario. A free text section at the end of the 
survey was included. 
 
The survey was piloted, reviewed and then circulated to members of the British Association 
of Stroke Physicians (BASP), Association of British Neurologists (ABN), Scottish 
Association of Neurological Science (SANS), British Cardiovascular Society (BCS), Scottish 
Cardiac Society (SCS) and Society of Acute Medicine (SAM) along with a cover letter 
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detailing the background of the project. It was also disseminated via the UK Clinical 
Research Networks. The survey was distributed via email with a hyperlink embedded 
allowing access to the survey. Responders were provided six weeks to complete the survey, 
with reminders sent 2 weeks prior to the closing date. Descriptive statistics were produced to 
describe responses.   
 
 
RESULTS  
Demographics: 
A total of 121 clinicians completed the survey. Responders were distributed throughout the 
UK with 54% from England, 31% from Scotland, 11% from Wales and 4% from Northern 
Ireland.  The commonest speciality of responders was Geriatric Medicine (n=88, 73%) 
followed by Neurology (n=18, 15%) and Acute Internal Medicine (n= 5, 4%). Three 
responders selected “other” but stated a special interest in stroke medicine. In the UK, acute 
stroke management is undertaken by either neurologists, geriatricians or internists with 
specialist interest in stroke medicine. Free text comments regarding timing of initiation of 
OAC are shown in Online-only Supplemental Table I. 
  
Use of OAC after stroke:  
One hundred and fifteen (95%) responders answered that there was uncertainty regarding 
when to administer OAC after AF-related ischaemic stroke. One hundred and four (86%) of 
the responders replied that they would be willing to participate in a clinical trial of early vs. 
later initiation of OAC. Forty-three (36%) responders used the 1-3-6-12 guidelines outlined 
by the ESC. Sixty (50%) responders reported using DOACs early after ischaemic stroke in 
patients with AF, 60 (50%) reported that their drug choice differed between patients but none 
reported a preference for VKA. 
Page 7 of 15 
 
 
TIA scenario: All responders reported that they currently initiate OAC within three days of a 
TIA (78% on the same day, median day 0, IQR day 0 to day 0) (Figure 1). The earliest and 
the latest acceptable times to start OAC in a clinical trial for patients with TIA are shown in 
Figure 2 (panel a and b).  
 
Mild stroke scenario: All responders reported that they currently initiate OAC within 15 
days of a mild stroke (10% on the same day and 71% within 7 days) (Figure 1).  The earliest 
and the latest acceptable times to start OAC in a clinical trial for patients with mild stroke are 
shown in Figure 2 (panel c and d). The median response regarding the earliest acceptable 
time to start OAC in a clinical trial was day 2 (IQR: day 0 -3). The median response 
regarding the latest time was day 7 (IQR: day 6 -14).  
 
Moderate stroke scenario: All responders reported that they currently initiate OAC within 
15 days of a moderate stroke (3% on the same day and 34% within 7 days) (Figure 1).  The 
earliest and the latest acceptable times to start OAC in a clinical trial for patients with 
moderate stroke are shown in Figure 3 (panel a and b). The median for the earliest acceptable 
time to start OAC in a clinical trial setting was day 5 (IQR: day 2 -day 7). Meanwhile, the 
median for the latest time of such was day 14 (IQR: day 10 -14). 
 
Severe stroke scenario: All responders reported that they currently initiate OAC within 20 
days of a severe stroke (0% on the same day and 2% within 7 days) (Figure 1).  The earliest 
and the latest acceptable times to start OAC in a clinical trial for patients with moderate 
stroke are shown in Figure 3 (panel c and d). The median for the earliest acceptable time to 
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start OAC in a clinical trial was day 10 (IQR: day 7 -14). Meanwhile, the median for the 
latest time of such was day 14 (IQR: day 14 -20).  
In the feedback section whilst a clinical trial measuring use of early vs. later initiation of 
DOACs in ischaemic stroke in patients with AF would be welcomed, opinions were mixed 
regarding the structure and intricacies of such a trial. The free text comments are shown in 
the Online-only Supplemental Table II. 
 
 
DISCUSSION  
The results of this UK-wide online survey amongst stroke physicians indicated that there was 
a lack of consensus regarding when to administer OAC after a stroke in patients with AF. It 
was clear from the survey that physicians felt that a clinical trial to answer this clinical 
conundrum would be beneficial.   
 
Current clinical practice was shaped during an era where warfarin was the only available oral 
drug. Warfarin, compared to acetylsalicylic acid, increases the risk of bleeding by two-thirds 
(2.2 vs. 1.3 events per 100 patient years).11 DOACs are at least as effective as warfarin for 
stroke prevention in AF and cause lower rates of intracranial haemorrhage. In the 
ARISTOTLE trial, the rate of intracranial haemorrhage was half with apixaban vs. warfarin 
(HR 0.51, 95% CI 0.35 to 0.70), and in the AVERROES trial it was similar to aspirin.12,13 
Similar data in comparison to warfarin have been shown for other DOACs.14,15,16 DOACs 
may therefore offer a better risk benefit ratio early after stroke but this cannot be concluded at 
present. Most trials of DOACs excluded patients who had suffered recent stroke, defined as 
within the last seven days after stoke onset, and in some trials much later. 
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Interestingly the survey found that only 36% of clinicians used the ‘1-3-6-12’ day outlined in 
ESC guidelines. However, from the responses, it is clear that most followed the basic 
principle of delaying OAC initiation in proportion to stroke severity. For those who did not 
use the ‘1-3-6-12’ rule, our free text comments suggest their decisions were based in a 
pragmatic way using their clinical judgement to assess for factors such as; swallow status, 
haemorrhagic transformation, likelihood of falls and size of infarct. The survey found little 
uncertainty regarding timing of OAC initiation after TIA. There was little disagreement in 
severe stroke but more uncertainty in cases of moderate stroke. Clinicians were also asked 
their opinions regarding the earliest/latest time for OAC intervention in the context of a 
clinical trial. Answers regarding the earliest and latest acceptable time points were more 
varied for severe and mild stroke, respectively. The nature of the uncertainty therefore differs 
with severity of stroke but exists nonetheless. It is clear that there is support from clinicians 
for a clinical trial in this area.  
 
We used an online survey and case vignettes. Each scenario was carefully selected, and all 
external risk factors were kept constant. This was to ensure the survey was easy to complete, 
and that we could identify clear patterns of practice that could inform trial design. There were 
no contraindications for OAC in each case although this oversimplification would not apply 
to real life clinical practice where many contraindications make the decision-making process 
more complex. To differentiate between the stroke severity in each of the cases provided, the 
definitions from the ELAN clinical protocol11 were used along with a National Institute of 
Health Stroke Scale (NIHSS) score. We felt, given the patient in each vignette had suffered 
TIA or stroke and had AF, that they were already of high risk of recurrence and had a 
CHA2DS2VASc score of at least 2 and that ABCD2 score may not alter decision to 
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anticoagulate. Our data do not allow us to explore how hyperacute thrombectomy therapy 
would influence decision-making.  
 
Limitations: The design of this survey had several limitations. There is a risk of selection 
bias, where clinicians with a more active interest in this subject, or perhaps with more 
uncertainty, were more likely to answer. Social-desirability bias was another potential 
limitation, where responders would answer in a way they thought they should answer rather 
than what they would actually do. The survey was anonymised to try to reduce bias. This was 
a UK survey so results may not be generalisable to other European and non-European 
countries. This may be particularly relevant given that most responders were trained in 
geriatric medicine. The multiple-choice options were kept short and the list was not 
exhaustive which may have caused some responders to answer too quickly or in an over 
simplistic manner. The survey was distributed via email with a hyperlink embedded allowing 
access to the survey. Thus, we were also unable to provide the proportion of active clinicians 
from each organisation who completed the survey. 
 
Future Directions: It is clear that randomised, controlled trials are needed to address this 
uncertainty. Four randomised, controlled clinical trials investigating early vs. late initiation of 
DOACs in patients with AF-related ischemic stroke have been initiated: Early versus Late 
initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN 
(ELAN, NCT03148457, Switzerland); OPtimal TIMing of Anticoagulation after AF-
associated acute ischaemic Stroke (OPTIMAS, British Heart Foundation, UK); Timing of 
Oral Anticogulant Therapy in Acute Ischaemic Stroke with Atrial Fibrillation (TIMING, 
NCT02961348, Sweden) and Optimal Delay Time to Initiate Anticoagulation After Ischemic 
Stroke in Atrial Fibrillation (START, NCT03021928, USA). Results are expected in 2021. 
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CONCLUSION 
This on-line survey of UK stroke physicians showed a lack of consensus for when to initiate 
OAC for patients with an acute stroke and AF, and clinical trials are needed.  
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FIGURES LEGENDS 
Figure 1: Response analysis of current initiation of OAC after TIA and stroke. 
 
Figure 2: The earliest and latest acceptable OAC initiation timings after TIA (a and b, 
respectively) and mild stroke (c and d, respectively) in patients with AF for a potential clinical 
trial. 
 
Figure 3: The earliest and latest acceptable OAC initiation timings after a moderate stroke (a 
and b, respectively) and severe stroke (c and d, respectively) in patients with AF for a 
potential clinical trial. 
